TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04252066: A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Sponsor: Amicus Therapeutics · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT04252066 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04252066 Rescue Dossier →